Boston Scientific Corporation

(New York Stock Exchange)

Top News rankings and signal summaries are processed using AI and may contain errors.

21
Slightly Bullish +15

Mizuho cuts Boston Scientific stock target to USD 55.00

Analyst downgrade Company update AI-generated analysis

Mizuho Securities has lowered its price target for Boston Scientific from USD 60.00 to USD 55.00 while maintaining an Outperform rating, citing concerns over near-term procedure volume pressure linked to Affordable Care Act and Medicaid changes ahead of the October 28 earnings report. Despite the...

Bullish Signals

  • Revenue grew 7.5% YoY to USD 5.44 billion.
  • Adjusted EPS surged 15% to USD 0.86.
  • Restructuring into three focused operational segments.
  • Appointed new COO Joseph M. Fitzgerald.

Bearish Signals

  • Mizuho cut price target 8.33% to $55 due to volume pressure.
  • ACA/Medicaid changes may hurt H2 2026 procedure volumes.
22
Somewhat Bearish -35

Oppenheimer cuts target for Boston Scientific stock from USD 85.00 to USD 65.00

Analyst downgrade Operational disruption AI-generated analysis

Oppenheimer has downgraded its price target for Boston Scientific stock from USD 85.00 to USD 65.00 following a significant cybersecurity incident that disrupted the company's manufacturing, order processing, and shipment operations. This negative analyst action reflects concerns regarding the impact of the breach on near-term...

Bullish Signals

  • Q2 2026 revenue hit $5.44B, up 7.50% YoY.

Bearish Signals

  • Oppenheimer downgraded price target from USD 85.00 to USD 65.00 due to cyber incident.
23
Somewhat Bearish -25

Boston Scientific stock slips after Citi downgrade and cyberattack fallout

AI-generated analysis

Boston Scientific stock closed at $43.55 on September 17, 2026, near its 52-week low following a downgrade by Citigroup and the lingering effects of an August cyberattack. The medical device manufacturer faces intensified competition in key markets while navigating operational disruptions that have temporarily impaired...

Bullish Signals

  • Q2 2026 organic sales grew 7% at guidance top end.

Bearish Signals

  • Citigroup downgraded BSX from Buy to Neutral, lowering target to $50.
  • August cyberattack disrupts operations and impairs customer order processing.
  • Intensifying competition in medical devices contributes to operational challenges.
24
Somewhat Bearish -35

Boston Scientific stock falls as cyberattack prompts guidance cut and BTIG lowers price target

AI-generated analysis

Boston Scientific (BSX) shares fell approximately 5.9% on September 9, 2026, after the medical device manufacturer announced that a significant cyberattack would prevent it from meeting its previously issued guidance for the third quarter and full year 2026. The cybersecurity incident, identified on August 25,...

Bullish Signals

  • Manufacturing resumed across most global facilities.
  • Distribution centers shipping orders at normal levels.
  • No impairment to device function or integrity.
  • Remote monitoring disruptions resolved and resuming.
  • Quality audits confirm complete product sterility.

Bearish Signals

  • Cyberattack prevents meeting Q3 and FY2026 guidance.
  • BTIG lowered price target from $60 to $56.
25
Bullish +55

Elevation Point Wealth Partners LLC Acquires 64,908 Shares of Boston ...

AI-generated analysis

Elevation Point Wealth Partners LLC significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 429.8% in the first quarter, adding 64,908 shares to reach a total holding of 80,011 shares valued at $5.02 million. Other institutional investors also adjusted positions, with FWL Investment Management...

Bullish Signals

  • Insiders bought 9,800 shares worth over $554,000 recently.
  • Q1 revenue grew 11.6% to $5.20 billion.
  • EPS beat expectations at $0.80 versus $0.79 consensus.
  • Management raised full-year 2026 EPS guidance to $3.34-$3.41.
  • Board authorized a $5 billion stock repurchase program.

Bearish Signals

  • Wolfe Research downgraded stock from outperform to peer perform.
  • Barclays cut price target from $96.00 to $89.00.
  • Wall Street Zen lowered rating from buy to hold.